Galderma, CH1335392721

Galderma stock: Mexico clears Restylane Shaype jawline use

Published on 11/18/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Galderma wins a first global jawline approval for Restylane Shaype in Mexico. Investors in Galderma stock now look to a launch planned for the first half of 2027.

Regulatory milestone and rollout

  • Mexico granted Restylane Shaype its first worldwide approval for a jawline indication.
  • Galderma plans to launch the product in Mexico during the first half of 2027.
  • The approval broadens the use of an existing aesthetic product and adds a new geography for the indication.
Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma announced on November 13 that Mexico approved Restylane Shaype for temporary chin augmentation and improved jawline definition. The company's announcement called the decision the product's first approval worldwide for a jawline indication.

Galderma said the approval expands Restylane Shaype's availability beyond chin augmentation in Mexico. The product is already approved for chin augmentation in several markets, including Europe, Brazil, Canada and Thailand.

Launch timing follows approval

The company expects to launch Restylane Shaype in Mexico during the first half of 2027. Commercial contribution will depend on the timing of the rollout and adoption by physicians and patients.

Restylane Shaype is a hyaluronic acid injectable designed for structural enhancement of the lower face. Galderma describes the formulation as a firmer gel intended to create a bone-mimicking effect while maintaining a natural appearance without surgery.

Galderma's release cited jawline data showing durable improvements for up to two years. It also said 70% of participants reported improved overall satisfaction with their appearance.

Quote remains below the prior report

Galderma stock traded at 202.90 euros on Lang & Schwarz at 17:32 CET on Wednesday, November 18, 2026. Since the November 17 report, the quote was 1.50% lower than the 206.00 euros cited there.

Galderma Group AG

  • Company: Galderma Group AG
  • ISIN: CH1335392721
  • Ticker: GALD.SW
  • Primary listing: SIX Swiss Exchange
  • Lang & Schwarz quote: 202.90 euros at 17:32 CET on Wednesday, November 18, 2026
  • Regulatory approval: Restylane Shaype for chin and jawline use in Mexico
  • Expected launch: First half of 2027

The broader market context is available in current market reports.

See More news and analyses on Galderma stock.

Disclaimer...
en | CH1335392721 | GALDERMA | boerse | 70531786 | bgmi